Clinical Trial Update: Peg-Intron and Rebetol Therapy in Treatment of Naive Hepatitis C Patients: A Comparison of Race and Genotype on Treatment Outcome (Study P04212) [Phase 4]

View source ↗

Summary

A Phase 4 trial in treatment-naive hepatitis C patients evaluated pegylated interferon alfa-2b (Peg-Intron) plus ribavirin (Rebetol) with a focus on race and ge…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• PEG Intron (pegylated interferon alfa-2b)
• Rebetol (ribavirin)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Hepatitis C, Chronic | Phase 4 | Status: TERMINATED | Results posted: 2010-01-06